Sign in
Taking peopleNo phase

Immune Response Profiling in Sepsis

Key facts

Who runs it
National University Hospital, Singapore
Where
Singapore1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
304 people, planned
Started
15 Jun 2026
Expected to end
1 Jul 2027
Type of study
Observational
Treatments tested
  • Microfluidic device for assessment of biophysical properties of white blood cells
Record updated
16 November 2026

Who can take part

Age
21 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age >/= 21 years old
  • Attending clinician suspects infection (including patients with unexplained fever or vague symptoms) OR
  • Patients who have a clear and objective source of systemic infection [such as pneumonia (infiltrates/consolidation on chest radiography), urinary tract infection (positive urinary leukocytes/nitrites), necrotising fasciitis (subcutaneous gas on plain radiograph or MRI-proven subcutaneous gas), hepatobiliary infection (chills and rigors, jaundice)]

Who cannot take part

  • Patients on medications that may result in macrocytosis: chemo agents, zidovudine, trimethoprim, phenytoin, oral contraceptive pills
  • Patients with medical conditions that may result in macrocytosis (that could interfere with evaluation of WBC size and deformability): vitamin B12 deficiency, primary bone marrow disorder, previous gastrectomy, pernicious anemia, alcoholism, COPD, familial macrocytosis, hypothyroidism, oncological patients (chemo agents can result in macrocytosis)
  • Severe neutropenia with white cell count of 0
  • Age < 21 years old
  • Pregnant patients
  • Unable to obtain informed consent
  • Unconscious patients or patients with no mental capacity to provide informed consent
  • Patients with "do-not-resuscitate" order

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 21 and 99 years old?

This trial is currently available in Singapore.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this prospective observational study is to investigate if a point-of-care testing device using microfluidics can evaluate the biophysical characteristics of white blood cells for the rapid diagnosis and prognosis of acute infection or sepsis.

Read full original descriptionShow less

Our main aim is to develop a rapid biophysical sparing assay protocol for the diagnosis and/or prognosis of acute infection and sepsis in the ED among patients with non-specific symptoms, by differentiating infection vs. non-infection in febrile cases, viral vs. bacterial cause of infection (if infection present) and low vs. high risk of sepsis with organ dysfunction.

The group in the trial

  • Prospective observational

    A total of 3 ml (slightly more than half teaspoon) of blood sample via intravenous cannulation in addition to clinically indicated full blood count will be collected from study participants and placed into EDTA vacutainer tubes. Automated aspiration of up to 100 µl of blood from the EDTA tube will be performed by the prototype and loaded onto the PDMS microfluidic device for the biophysical assay.

    Treatment: Microfluidic device for assessment of biophysical properties of white blood cells

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Point-of-care, Label-free Platform Technology Profiling the Immune Response - With Sepsis as the Initial Indication
Criteria questions
Built from NCT07937839, who can take part
Record updated
16 November 2026